Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
34 studies found for:    " August 03, 2011":" September 02, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" August 03, 2011":" September 02, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
Condition: HIV Infections
Interventions: Biological: HIVAX;   Biological: saline solution;   Biological: Saline solution
2 Recruiting the ANRS CO21 " Extreme " Cohort (CODEX)
Condition: HIV Infection
Intervention: Biological: blood sampling
3 Completed Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
Condition: HIV Infections
Interventions: Biological: Sub C gp140 Vaccine;   Biological: MF59C.1 Adjuvant;   Other: Sodium chloride
4 Completed An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
Condition: Human Immunodeficiency Virus; HIV
Interventions: Drug: Darunavir/Ritonavir (DRV/r);   Drug: Efavirenz (EFV)
5 Completed Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events
Condition: HIV-Infection
Intervention: Other: Time of starting antiretroviral therapy
6 Completed Safety Study of Maraviroc's Effect on Human Osteoclasts
Conditions: HIV Infections;   AIDS
Intervention: Drug: Maraviroc
7 Terminated Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Conditions: Human Immunodeficiency Virus;   Lipohypertrophy
Intervention: Drug: Raltegravir-Maraviroc
8 Unknown  HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users
Conditions: HIV;   Drug Use Disorders
Interventions: Behavioral: HEART to HAART;   Behavioral: adherence counseling with the addition of smartphone control
9 Completed DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects
Condition: HIV
Interventions: Drug: Twice-daily Darunavir/ritonavir;   Drug: Once-daily Darunavir/ritonavir
10 Completed Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction
Condition: HIV
Intervention: Dietary Supplement: Moringa oleifera
11 Completed
Has Results
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers
Conditions: Hepatitis C;   HIV
Intervention: Drug: boceprevir; etravirine
12 Completed
Has Results
Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi
Condition: HIV
Interventions: Other: Home assessment and initiation of ART;   Other: Clinic-based ART assessment and initiation
13 Completed Targeting Interventions at Venues Where Risk of HIV Transmission is High
Condition: HIV
Intervention: Other: Condom distribution and peer education
14 Completed HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
Conditions: HIV Infection;   Hepatitis C
Intervention:
15 Unknown  Drug Exposure Registry for GSK2248761, an Investigational NNRTI
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK2248761
16 Completed AIMS Study: Improving HIV Treatment Adherence
Condition: HIV
Interventions: Behavioral: Treatment as usual;   Behavioral: AIMS intervention
17 Completed Integrated Mental Health Treatment & HIV Prevention for Court-Involved Youth
Condition: HIV Prevention
Interventions: Behavioral: Integrated treatment program;   Behavioral: Treatment as Usual
18 Completed Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% vaginal gel;   Drug: Depo-medroxyprogesterone acetate (DMPA);   Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
19 Completed Drug Interaction Study Between Dolutegravir and Prednisone
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir;   Drug: Prednisone
20 Completed A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: GSK1265744 injectable suspension;   Other: Placebo to match injectable suspension

   Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.